Search results
16 wrz 2024 · Pfizer-BioNTech COVID-19 vaccine 2024-2025 formula is authorized for people ages 6 months through 11 years. Comirnaty is approved for people age 12 and older. The vaccines that help protect against COVID-19 are safe and effective based on clinical trials and continued monitoring.
28 sie 2024 · Pfizer-BioNTech COVID-19 Vaccine is indicated for individuals 5 through 11 years of age (via a 10mcg / 0.3mL single-dose vial presentation) and for individuals 6 months through 4 years of age (via a 3mcg / 0.3mL multi-dose vial (3 doses per vial) presentation).
The Pfizer–BioNTech COVID-19 vaccine is used to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus, by eliciting an immune response to the S antigen. [ 1 ] [ 2 ] [ 31 ] [ 40 ] The vaccine is used to reduce morbidity and mortality from COVID-19.
11 gru 2020 · COMIRNATY ® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech. It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older; It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:
22 sie 2024 · The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and...
4 paź 2021 · EMA’s human medicines committee (CHMP) has concluded that an extra dose of the COVID-19 vaccines Comirnaty (BioNTech/Pfizer) and Spikevax (Moderna) may be given to people with severely weakened immune systems, at least 28 days after their second dose.
20 wrz 2024 · Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European ...
